Livzon Pharmaceutical Group News and Activities
Presence
Livzon Pharmaceutical Group develops, manufactures, and sells pharmaceutical products and healthcare services. Its main offerings include prescription medicines, active ingredients, diagnostics, and wellness products for hospitals, clinics, and consumers.
Livzon Pharmaceutical Group products and services overview:
- Prescription medicines
- Active ingredients
- Diagnostic products
- Biologic drugs
- Wellness products
- Healthcare services
Revenue: ~$2 billion
Employees: 9,000
Headquarters: Zhuhai, China
Livzon Pharmaceutical Group is one of the...
Livzon Pharmaceutical Group is a company listed under the stock ticker 000513 (CN).
Executives
View the org chart displaying its 4 main executives
Most searched biographies at Livzon Pharmaceutical Group
- Yanggang Tang, President and Executive Director
- Desheng Tao, Vice Chairman of the Board and Non-Executive Director
- Guoxiang Xu, Vice Chairman of the Board, Vice President and Execut...
Create your alert
to follow the executive moves at Livzon Pharmaceutical Group.
Pharmaceuticals
Livzon Pharmaceutical Group has 1,913 competitors including Sanofi (France), Eli Lilly (United States (USA)) and Moderna (United States (USA)).
Popular M&A news in Pharmaceuticals
- Corden Pharma has announced the acquisition of AmbioPharm (posted on June 5 2026).
- Laboratoire Servier has announced the acquisition of Edgewise Therapeutics (posted on June 4 2026).
- Contraline has just announced a $93 Million fundraising (posted on June 3 2026).
Popular contacts in Pharmaceuticals
News
Press releases by Livzon Pharmaceutical Group
- Board Diversity Policy_Sustainable Development_Livzon
- Tax Policy_Sustainable Development_Livzon
- Philanthropy_Sustainable Development_Livzon
- Suppliers_Sustainable Development_Livzon
- Environment, Occupational Health and Safety (EHS)_Sustainable Development_Livzon
- Human Development_Sustainable Development_Livzon
- Business Ethics_Sustainable Development_Livzon
- Livzon Group Won “Top 10 of Private Enterprise in Zhuhai”_Livzon
- Employment system_News Center_Livzon
- A Recombinant SARS-Cov-2 Fusion Protein Vaccine (V-01) developed and manufactured by Livzon has shown good protective effects against the Omicron variant in a phase III clinical booster trial_Livzon
- View more press releases Close
Social media about Livzon Pharmaceutical Group
- Livzon Pharmaceutical Group on Wikipedia, Google News & Yahoo Finance
- Livzon Pharmaceutical Group on LinkedIn, X (Twitter) & YouTube
